KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dynavax Technologies (DVAX) Current Deferred Revenue: 2009-2021

Historic Current Deferred Revenue for Dynavax Technologies (DVAX) over the last 9 years, with Dec 2021 value amounting to $349.9 million.

  • Dynavax Technologies' Current Deferred Revenue fell 75.63% to $87.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was $87.4 million, marking a year-over-year decrease of 75.63%. This contributed to the annual value of $349.9 million for FY2021, which is 815.59% up from last year.
  • As of FY2021, Dynavax Technologies' Current Deferred Revenue stood at $349.9 million, which was up 815.59% from $38.2 million recorded in FY2020.
  • Dynavax Technologies' 5-year Current Deferred Revenue high stood at $349.9 million for FY2021, and its period low was $38.2 million during FY2020.
  • Its 2-year average for Current Deferred Revenue is $194.0 million, with a median of $194.0 million in 2020.
  • Data for Dynavax Technologies' Current Deferred Revenue shows a peak YoY spiked of 815.59% (in 2021) over the last 5 years.
  • Over the past 2 years, Dynavax Technologies' Current Deferred Revenue (Yearly) stood at $38.2 million in 2020, then skyrocketed by 815.59% to $349.9 million in 2021.